223 related articles for article (PubMed ID: 35224096)
21. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.
Wimmer CD; Rentsch M; Crispin A; Illner WD; Arbogast H; Graeb C; Jauch KW; Guba M
Kidney Int; 2007 Jun; 71(12):1271-8. PubMed ID: 17332737
[TBL] [Abstract][Full Text] [Related]
22. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
23. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
24. De novo head and neck cancer arising in solid organ transplantation recipients: The Asan Medical Center experience.
Park MJ; Roh JL; Choi SH; Nam SY; Kim SY; Lee YS
Auris Nasus Larynx; 2018 Aug; 45(4):838-845. PubMed ID: 29150348
[TBL] [Abstract][Full Text] [Related]
25. Malignancy following renal transplantation.
Yang TC; Shu KH; Cheng CH; Wu MJ; Lian JD
Zhonghua Yi Xue Za Zhi (Taipei); 1998 May; 61(5):281-8. PubMed ID: 9650432
[TBL] [Abstract][Full Text] [Related]
26. De Novo Malignancies After Liver Transplantation: A Single Institution Experience.
Egeli T; Unek T; Ozbilgin M; Agalar C; Derici S; Akarsu M; Unek IT; Aysin M; Bacakoglu A; Astarcıoglu I
Exp Clin Transplant; 2019 Feb; 17(1):74-78. PubMed ID: 29237362
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database.
Sampaio MS; Cho YW; Qazi Y; Bunnapradist S; Hutchinson IV; Shah T
Transplantation; 2012 Nov; 94(10):990-8. PubMed ID: 23085553
[TBL] [Abstract][Full Text] [Related]
28. Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience.
Zilinska Z; Sersenova M; Chrastina M; Breza J; Bena L; Baltesova T; Jurcina A; Roland R; Lackova E; Cellar M; Laca L; Dedinska I
Neoplasma; 2017; 64(2):311-317. PubMed ID: 28052685
[TBL] [Abstract][Full Text] [Related]
29. Early de novo malignancies after kidney transplantation.
Veroux M; Puliatti C; Fiamingo P; Cappello D; Macarone M; Puliatti D; Vizcarra D; Gagliano M; Veroux P
Transplant Proc; 2004 Apr; 36(3):718-20. PubMed ID: 15110643
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey.
Karakoyun M; Önen Ş; Baran M; Çakır M; Ömür Ecevit Ç; Kılıç M; Kantar M; Aksoylar S; Özgenç F; Aydoğdu S
Turk J Gastroenterol; 2018 Jan; 29(1):89-93. PubMed ID: 29391313
[TBL] [Abstract][Full Text] [Related]
31. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
[TBL] [Abstract][Full Text] [Related]
32. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
33. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
34. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
35. Incidence and treatment of neoplasia after transplantation.
Penn I
J Heart Lung Transplant; 1993; 12(6 Pt 2):S328-36. PubMed ID: 8312352
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
37. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
38. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
[TBL] [Abstract][Full Text] [Related]
39. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France.
Farge D
Eur J Med; 1993; 2(6):339-43. PubMed ID: 8252179
[TBL] [Abstract][Full Text] [Related]
40. Malignancy in pediatric transplant recipients.
Buell JF; Gross TG; Thomas MJ; Neff G; Muthiah C; Alloway R; Ryckman FC; Tiao GM; Woodle ES
Semin Pediatr Surg; 2006 Aug; 15(3):179-87. PubMed ID: 16818139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
